Mark P. Breazzano, MD

Articles by Mark P. Breazzano, MD

Unmet Needs and the Future of Wet AMD Care

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.

Clinical Trials of Alternative Targets in Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.

Emerging Treatments for Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.

Diagnostic Imaging of Nonexudative Neovascular AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

A panel of experts discusses nonexudative neovascular AMD and challenges associated with diagnostic imaging such as OCT-A and fluorescein angiography.

Factors to Consider When Selecting Therapy in Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.

Theoretical Systemic Safety of Anti-VEGF in Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.

Safety and Efficacy of Available Treatments in Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Experts compare the safety and efficacy of agents currently available for wet AMD treatment and emphasize the importance of post-marketing surveillance.

Anti-VEGF Treatment for Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Panelists give insight into the role of anti-VEGF therapy for wet AMD treatment and share personal experiences counseling patients on the goals of therapy.

Managing Treatment Burden for Patients With Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 23rd 2021

Experts share best practices for managing the treatment burden of wet AMD including treat-and-extend, loading doses, monitoring, and hybrid telemedicine.

Impact of COVID-19 on Management of Wet AMD

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 22nd 2021

A panel of experts considers the impact of COVID-19 on wet AMD management and discusses the potential for telemedicine and home monitoring devices.

An Overview of Age-Related Macular Degeneration

ByCharles Wykoff, MD, PHD,Diana Do, MD,Mark P. Breazzano, MD,Sophie J. Bakri, MD

March 22nd 2021

Key opinion leaders in ophthalmology provide an overview of age-related macular degeneration and comment on clinical recommendations for assessing symptoms.